MAP2K4 — Mitogen-Activated Protein Kinase Kinase 4
Introduction
MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4), also known as MKK4 or JNKK1, is a dual-specificity protein kinase that serves as a critical node in cellular stress signaling. It phosphorylates and activates both the JNK (c-Jun N-terminal kinase) and p38 MAPK pathways, making it a central regulator of stress responses, apoptosis, and cell survival in the brain[@davis2022].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">MAP2K4 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>MAP2K4</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>MKK4, JNKK1, MEK4, SKK4</td></tr>
<tr><td><strong>Full Name</strong></td><td>Mitogen-Activated Protein Kinase Kinase 4</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>17p12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5606](https://www.ncbi.nlm.nih.gov/gene/5606)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P45985](https://www.uniprot.org/uniprot/P45985)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157873</td></tr>
<tr><td><strong>Protein Size</strong></td><td>399 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Protein Structure and Function
Kinase Domain Architecture
...MAP2K4 — Mitogen-Activated Protein Kinase Kinase 4
Introduction
MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4), also known as MKK4 or JNKK1, is a dual-specificity protein kinase that serves as a critical node in cellular stress signaling. It phosphorylates and activates both the JNK (c-Jun N-terminal kinase) and p38 MAPK pathways, making it a central regulator of stress responses, apoptosis, and cell survival in the brain[@davis2022].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">MAP2K4 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>MAP2K4</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>MKK4, JNKK1, MEK4, SKK4</td></tr>
<tr><td><strong>Full Name</strong></td><td>Mitogen-Activated Protein Kinase Kinase 4</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>17p12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5606](https://www.ncbi.nlm.nih.gov/gene/5606)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P45985](https://www.uniprot.org/uniprot/P45985)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157873</td></tr>
<tr><td><strong>Protein Size</strong></td><td>399 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Protein Structure and Function
Kinase Domain Architecture
MAP2K4 contains:
- N-terminal docking domain: For interaction with substrates and upstream kinases
- Kinase domain: Catalytic core with dual-specificity
- C-terminal regulatory region: Contains serine/threonine residues for activation
Catalytic Activity
As a dual-specificity kinase, MAP2K4:
| Substrate | Activation Site | Downstream Effect |
|-----------|-----------------|-------------------|
| JNK1/2/3 | Thr183/Tyr185 | AP-1 activation, apoptosis |
| p38α/β | Thr180/Tyr182 | Inflammation, stress response |
Activation Mechanism
MAP2K4 is activated by:
MAP3K phosphorylation: MEKK1-4, MLK3, TAK1, TAOK1/2/3
Dual phosphorylation: On S/T-Y residues in the activation loop
JNK-specific activation: Can be regulated by scaffold proteinsStructural Features
The MAP2K4 protein contains several key structural features[@gavron2019]:
- N-terminal D-domain: Conserved docking motif for interaction with upstream MAP3Ks and downstream MAPK substrates
- Kinase domain (aa 80-330): Contains the catalytic core with the dual-specificity activity
- Activation loop: Contains the critical S222 and S228 phosphorylation sites
- C-terminal regulatory region: Modulates interaction with scaffolds and localization
Signaling Pathways
MAP2K4/JNK/p38 Cascade
Mermaid diagram (expand to render)
Cellular Functions
| Function | Pathway | Outcome |
|----------|---------|---------|
| Stress Response | p38 | Cytokine production, cell adaptation |
| Apoptosis | JNK | Pro-apoptotic signaling in neurons |
| Inflammation | p38 | Neuroinflammatory responses |
| Synaptic Plasticity | JNK | Excitotoxicity, memory impairment |
Expression Patterns
Brain Distribution
- Hippocampus: High expression in CA1-CA3 and dentate gyrus
- Cortex: All layers, particularly layers II-III and V
- Cerebellum: Purkinje cells and granule cells
- Substantia Nigra: Dopaminergic neurons
Cellular Localization
- Neurons: Cytoplasmic and nuclear compartments
- Astrocytes: Induced under stress conditions
- Microglia: Activated state expression
Role in Neurodegeneration
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease)[@kim2021]:
JNK Activation: Correlates with [tau](/proteins/tau-protein) pathology and neurofibrillary tangle formation
Amyloid-β Effects: Aβ oligomers activate MAP2K4/JNK pathway
Synaptic Dysfunction: JNK-mediated phosphorylation of synaptic proteins
Neuronal Apoptosis: MAP2K4 contributes to Aβ-induced neuronal deathParkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease)[@morel2020]:
Dopaminergic Vulnerability: MAP2K4/JNK pathway activated in [substantia nigra](/brain-regions/substantia-nigra) neurons
Mitochondrial Toxins: MPTP, 6-OHDA activate JNK pathway
α-Synuclein Pathology: Aggregation triggers MAP2K4 signaling
Neuroprotection: JNK inhibitors protect dopaminergic neuronsAmyotrophic Lateral Sclerosis
- Motor Neuron Degeneration: MAP2K4/JNK pathway activated in ALS models
- Excitotoxicity: Contributes to glutamate-induced motor neuron death
- Therapeutic Target: JNK inhibitors show promise in preclinical models
Stroke and Brain Injury
- Ischemic Damage: Strong activation of JNK pathway following stroke
- Neuroprotection: MAP2K4 inhibition reduces infarct size in models
- Therapeutic Window: Potential for intervention post-stroke
Therapeutic Implications
Drug Development
| Approach | Status | Target |
|----------|--------|--------|
| JNK Inhibitors | Clinical trials | c-Jun, JNK pathway |
| p38 Inhibitors | Clinical trials | Inflammatory responses |
| MAP2K4 Modulators | Preclinical | Pathway activation |
Biomarkers
- Phospho-JNK levels: Potential marker for neuronal stress
- MAP2K4 activity: Could indicate disease progression
Research Directions
Brain-penetrant JNK inhibitors: For neurodegenerative diseases
Combination therapies: With antioxidants or neuroprotective agents
Gene therapy: Targeting upstream activatorsInteractions
| Interactor | Type | Relationship |
|------------|------|--------------|
| MAP3K1-4 | Kinase | Upstream activators |
| JNK1/2/3 | Kinase | Substrate |
| p38α/β | Kinase | Substrate |
| JIP1/2/3 | Scaffold | Localization |
| ATF2 | Transcription factor | Downstream target |
MAP2K4 exhibits differential activation of MAPK isoforms:
| MAP2K4 Activity | JNK Isoforms | p38 Isoforms | Physiological Outcome |
|-----------------|--------------|--------------|----------------------|
| High | JNK1/JNK2 | p38α | Strong pro-apoptotic signaling |
| Moderate | JNK3 | p38β | Tissue-specific effects |
| Low | JNK1/2 | p38γ/δ | Stress adaptation |
Negative Regulation
MAP2K4 activity is negatively regulated by:
- MAPK phosphatases (MKPs): DUSP1, DUSP2, DUSP10 dephosphorylate MAP2K4
- Inhibitory phosphorylation: Serine/threonine phosphatases reverse activation
- Protein inhibitors: Specific protein inhibitors of MAP2K4
Therapeutic Implications
Drug Development
| Approach | Status | Target |
|----------|--------|--------|
| JNK Inhibitors | Clinical trials | c-Jun, JNK pathway |
| p38 Inhibitors | Clinical trials | Inflammatory responses |
| MAP2K4 Modulators | Preclinical | Pathway activation |
| Dual JNK/p38 Inhibitors | Preclinical | Broader pathway inhibition |
Biomarkers
- Phospho-JNK levels: Potential marker for neuronal stress
- MAP2K4 activity: Could indicate disease progression
- Phospho-p38: Inflammatory biomarker
Research Directions
Brain-penetrant JNK inhibitors: For neurodegenerative diseases
Combination therapies: With antioxidants or neuroprotective agents
Gene therapy: Targeting upstream activators
Scaffold disruptors: Blocking pathological MAP2K4 interactionsSee Also
- [JNK Signaling Pathway](/mechanisms/jnk-signaling)
- [p38 MAPK Pathway](/mechanisms/p38-mapk-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Apoptosis Pathways](/mechanisms/apoptosis-pathways)
- [Neurodegeneration](/diseases/neurodegeneration)
- [Stress Response Pathways](/mechanisms/cellular-stress-response)
References
[Davis RJ, et al. MAP kinase signaling in neurodegeneration. Cell (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Kim HJ, et al. JNK signaling in Alzheimer's disease. Nature Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Wagner EF, Nebreda AR. Signal integration by the MAP kinase pathways. Nature Reviews Cancer (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Morel C, et al. MAPK pathways and their role in Parkinson's disease. Progress in Neurobiology (2020)](https://pubmed.ncbi.nlm.nih.gov/32145678/)
[Yarwood CE, et al. Targeting JNK pathway for neuroprotection in stroke. Neurotherapeutics (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Gavrila A, et al. MAP2K4 mutations in cancer and neurological disorders. Oncogene (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)